Skip to content

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 11-15, 2023, in Boston, MA.  

Aprea is in development with two assets. Its lead program is ATRN-119, a clinical-stage small-molecule ATR inhibitor being developed for solid tumor indications. It is currently in an ongoing Phase 1/2a trial; details for which can be found here: The company’s second asset, ATRN-1051, is an oral, small-molecule WEE1 inhibitor; Aprea anticipates filing an IND submission in the fourth quarter of 2023.

Details of the poster presentations are as follows:

Poster #1 
Title:First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
Abstract #:C034
Session:Session C; Level 2, Exhibit Hall D
Date/Time:Saturday, October 14 | 12:30pm – 4:00 pm ET
Presenter:Nadeem Q Mirza, M.D., M.P.H., Aprea Therapeutics, Inc.
Poster #2 
Title:The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well-tolerated and effective cancer treatments
Abstract #:C147
Session:Session C; Level 2, Exhibit Hall D
Date/Time:Saturday, October 14 | 12:30pm – 4:00 pm ET
Presenter:Eric J. Brown, Ph.D., Perelman School of Medicine, University of Pennsylvania

In addition to the two poster presenters, Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will be in attendance at the poster sessions and conference.

About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small-molecule ATR inhibitor in development for solid tumor indications. Our oral, small-molecule WEE1 inhibitor is being advanced to IND submission. For more information, please visit the company website at

The Company may use, and intends to use, its investor relations website at as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are submits to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials, futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results )including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statement for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors